Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.305 USD | -1.15% | -9.61% | -35.64% |
May. 23 | Transcript : Altimmune, Inc. Presents at UBS Obesity Therapeutics Day, May-23-2024 10:00 AM | |
May. 09 | Transcript : Altimmune, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-35.64% | 524M | C | ||
+11.64% | 116B | B+ | ||
+12.19% | 106B | B+ | ||
-9.22% | 23.89B | B+ | ||
-2.62% | 21.58B | B | ||
-10.81% | 18.96B | A- | ||
-40.50% | 16.96B | A- | ||
-14.69% | 16.33B | B | ||
+7.35% | 14.14B | C+ | ||
+30.56% | 12.02B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ALT Stock
- Ratings Altimmune, Inc.